Cargando…

SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Narowski, Tara M., Raphel, Kristin, Adams, Lily E., Huang, Jenny, Vielot, Nadja A., Jadi, Ramesh, de Silva, Aravinda M., Baric, Ralph S., Lafleur, John E., Premkumar, Lakshmanane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769879/
https://www.ncbi.nlm.nih.gov/pubmed/35090596
http://dx.doi.org/10.1016/j.celrep.2022.110336
_version_ 1784635242217209856
author Narowski, Tara M.
Raphel, Kristin
Adams, Lily E.
Huang, Jenny
Vielot, Nadja A.
Jadi, Ramesh
de Silva, Aravinda M.
Baric, Ralph S.
Lafleur, John E.
Premkumar, Lakshmanane
author_facet Narowski, Tara M.
Raphel, Kristin
Adams, Lily E.
Huang, Jenny
Vielot, Nadja A.
Jadi, Ramesh
de Silva, Aravinda M.
Baric, Ralph S.
Lafleur, John E.
Premkumar, Lakshmanane
author_sort Narowski, Tara M.
collection PubMed
description Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals.
format Online
Article
Text
id pubmed-8769879
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s).
record_format MEDLINE/PubMed
spelling pubmed-87698792022-01-20 SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people Narowski, Tara M. Raphel, Kristin Adams, Lily E. Huang, Jenny Vielot, Nadja A. Jadi, Ramesh de Silva, Aravinda M. Baric, Ralph S. Lafleur, John E. Premkumar, Lakshmanane Cell Rep Article Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals. The Author(s). 2022-02-01 2022-01-20 /pmc/articles/PMC8769879/ /pubmed/35090596 http://dx.doi.org/10.1016/j.celrep.2022.110336 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Narowski, Tara M.
Raphel, Kristin
Adams, Lily E.
Huang, Jenny
Vielot, Nadja A.
Jadi, Ramesh
de Silva, Aravinda M.
Baric, Ralph S.
Lafleur, John E.
Premkumar, Lakshmanane
SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title_full SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title_fullStr SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title_full_unstemmed SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title_short SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
title_sort sars-cov-2 mrna vaccine induces robust specific and cross-reactive igg and unequal neutralizing antibodies in naive and previously infected people
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769879/
https://www.ncbi.nlm.nih.gov/pubmed/35090596
http://dx.doi.org/10.1016/j.celrep.2022.110336
work_keys_str_mv AT narowskitaram sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT raphelkristin sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT adamslilye sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT huangjenny sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT vielotnadjaa sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT jadiramesh sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT desilvaaravindam sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT baricralphs sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT lafleurjohne sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople
AT premkumarlakshmanane sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople